Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival
JCO Precision Oncology · 2026-03 · 10 (3)
DOI: 10.1200/po-25-01171 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-03. Verfasst von Hely Ollila und 6 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Pleural Neoplasms, Mesothelioma, Malignant, Mesothelioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Although we typically consider diffuse pleural mesothelioma (DPM) as a disease of elderly males with a history of asbestos exposure, young individuals are also affected. Given the increasing incidence of cancer in young individuals, we investigated the characteristics and underlying biology of young patients with DPM. METHODS We identified patients with DPM age ≤50 years from Memorial Sloan Kettering Cancer Center (1990-2023). Clinicopathologic and genetic characteristics were compared between very young (≤35 years) and young (36-50 years) patients. RESULTS We identified 273 patients with DPM age ≤50 years; 39% were female, 40% had a history of self-reported occupational asbestos exposure (very young, 16% v young, 45%; P < .01), 16% had a personal history of cancer (very young, 7% v young, 18%; P = .07), and 70% had a family history of cancer (most commonly breast, lung, and colon). Most frequently altered somatic genes (51/273 tested; 46/51 positive) included BAP1 (22/47, 47%), NF2 (18/47, 38%), CDKN2A/B (12/48, 25%), and TP53 (10/48, 21%). Very young patients had less somatic alterations in BAP1 (13% v 63%, P < .01) and a lower tumor mutational burden (0.9 v 1.8 mut/mB, P < .01); they were less frequently carriers of germline alterations (0% [0/8] v 43% [6/14], P = .05). Somatic alterations in CDKN2B were more frequent among females (females 42% v males 12%, P = .03). CONCLUSION Young patients with DPM have strong personal and family histories of cancer, and heterogeneous somatic and germline alterations, indicating divergent underlying biology. With the increasing prevalence of young adults with cancers, mesotheliomas, although uncommon, should be on the differential for patients even without asbestos exposure history in this age group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
ORCID-Profile: Amina Tidjani, Jennifer L Sauter, Soo-Ryum Yang, Charles B Simone, Michael Offin, Prasad S Adusumilli
Förderung
- NCI NIH HHS
Zitieren
APA
Ollila, H., Tidjani, A., Sauter, J. L., Yang, S. R., Simone, C. B., Offin, M., & Adusumilli, P. S. (2026). Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival. JCO Precision Oncology, 10(3). https://doi.org/10.1200/po-25-01171
Vancouver
Ollila H, Tidjani A, Sauter JL, Yang SR, Simone CB, Offin M, et al. Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival. JCO Precision Oncology. 2026;10(3). doi:10.1200/po-25-01171
BibTeX
@article{Ollila2026,
author = {Ollila, Hely and Tidjani, Amina and Sauter, Jennifer L and Yang, Soo-Ryum and Simone, Charles B and Offin, Michael and Adusumilli, Prasad S},
title = {Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {3},
doi = {10.1200/po-25-01171}
}
EUVIMED